MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 889 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Fórmula:C24H21ClF2N4O3Forma y color:SolidPeso molecular:486.9ADT-1004
CAS:ADT-1004 is an inhibitor of RAS. It can be used for research involving Ras-mediated diseases.Fórmula:C33H36FN3O6Forma y color:SoildPeso molecular:589.65p38α MAPK/CK1δ inhibitor-1
CAS:<p>p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.</p>Fórmula:C24H17FN6O2Forma y color:SolidPeso molecular:440.429SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Fórmula:C15H13F2NO4S2Forma y color:SolidPeso molecular:373.395KRAS G12C inhibitor 56
CAS:KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.Fórmula:C32H39N7O4SForma y color:SolidPeso molecular:617.76KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Fórmula:C14H13NO4Forma y color:SolidPeso molecular:259.26JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Fórmula:C25H33ClN6O5Forma y color:SolidPeso molecular:533.02KRAS G12C inhibitor 20
CAS:<p>KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.</p>Fórmula:C33H37ClFN7O3Forma y color:SolidPeso molecular:634.14p38 MAPK-IN-6
CAS:<p>p38 MAPK-IN-6 (compound c47) is an inhibitor of p38 MAPK, exhibiting a 14% inhibition rate at a concentration of 10 μM.</p>Fórmula:C16H14BrN3OS2Forma y color:SolidPeso molecular:408.336KRAS inhibitor-21
CAS:KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.Fórmula:C33H41N5O3Forma y color:SolidPeso molecular:555.71SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Fórmula:C26H28ClFN6Forma y color:SolidPeso molecular:478.992MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Fórmula:C25H24N4O2Forma y color:SolidPeso molecular:412.48KRAS inhibitor-37
CAS:KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.Fórmula:C32H33ClFN7O3Forma y color:SolidPeso molecular:618.10Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Fórmula:C26H27ClN4OForma y color:SolidPeso molecular:446.972PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OForma y color:SolidPeso molecular:681.05KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Fórmula:C30H30F2N4O4Forma y color:SolidPeso molecular:548.58Everafenib
Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.Fórmula:C20H23ClFN5O2S2Forma y color:SolidPeso molecular:484.01J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Fórmula:C38H32N2O12Pureza:98%Forma y color:SolidPeso molecular:708.67MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Fórmula:C19H20N2O3Forma y color:SolidPeso molecular:324.37HPK1-IN-14
CAS:<p>HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.</p>Fórmula:C24H23FN6O2Forma y color:SolidPeso molecular:446.48
